Setara Biosciences
Setara Biosciences is a San Diego-based clinical-stage biotech formed by former Actio Biosciences leaders after Jazz Pharmaceuticals acquired Actio.
Position in SVTRnew
Snapshot 2026-10-31- Startup SignalsRankedof 2,234
- Life SciencesRankedof 238
- Drug DiscoveryRankedof 66
About
Setara Biosciences is a San Diego-based clinical-stage biotech formed by former Actio Biosciences leaders after Jazz Pharmaceuticals acquired Actio. It develops small-molecule precision medicines for rare genetic diseases using genetics, drug discovery and data science; lead asset STAR-0871 (formerly ABS-0871), an oral TRPV4 inhibitor, is in Phase 1a for CMT2C and overactive bladder.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 11
Investor· 7
Founders / team· 4
Funding history
- 2026-10-30Series A$90M
Investors · Deerfield Management, Canaan Partners, Droia Ventures, EcoR1, Euclidean Capital, Regeneron Ventures, Jazz PharmaceuticalsSource · fiercebiotech.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Setara Biosciences
Setara Biosciences is a San Diego-based clinical-stage biotech formed by former Actio Biosciences leaders after Jazz Pharmaceuticals acquired Actio. It develops small-molecule precision medicines for rare genetic diseases using genetics, drug discovery and data science; lead asset STAR-0871 (formerly ABS-0871), an oral TRPV4 inhibitor, is in Phase 1a for CMT2C and overactive bladder.
Series A · 2026-10
—
United States
BusinessLatest roundTotal raisedDate- Ecotone
Genomic foundation model (diffusion transformer dnaSORA) that locates disease-causing DNA sequences in rare genetic diseases, for pharma and biotech drug discovery
— - PsiThera
Oral small-molecule drugs for immune and inflammatory diseases, using AI to model protein "kinetics" (QUAISAR™ platform)
Series A · $48M · 2025-12
$48M - Leash Biosciences
Uses AI and machine learning to predict small-molecule drug candidates for any protein
Seed · $9M · 2024-04
$9M
China
BusinessLatest roundTotal raisedDate- NeuShen Therapeutics
Novel drugs for CNS psychiatric and neurological disorders, with the NeuChime small-molecule discovery platform and NeuGem AAV gene therapy platform; lead programs include NS-136 (M4 positive allosteric modulator) and NS-041 (KCNQ2/3 activator)
Series B · 2026-09
— - AIPher
AI-native drug discovery: proprietary drug foundation models and AI agent engine for early discovery of novel small-molecule, peptide and other drugs
Angel · 2026-09
— - MindRank
Designs and develops novel small-molecule drugs using its in-house AI drug discovery platform MAP
Series B · $52M · 2026-07
$52M
Europe
BusinessLatest roundTotal raisedDate- Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M - Allox
Allox is a Barcelona techbio spun out of the Centre for Genomic Regulation (CRG) in 2023, combining deep mutational scanning, high-throughput phenotyping and AI-driven biophysical modelling to map allosteric sites and develop small molecules against hard-to-drug targets; lead candidate ALX-001 is preclinical.
Seed · 2026-10
— - Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B
Other / unspecified
BusinessLatest roundTotal raisedDate- Mithril Medicine
Antibody drug development for rare muscular dystrophies, using AI agents to coordinate outsourced labs.
— - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - Congruence
Computation-driven drugs for genetic diseases (including CGX-926)
Undisclosed · $32M · 2025-09
$32M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Y Combinator
39 Life Sciences deals in the last 24 months · 34 at a nearby stage · 32 in US West Coast
Request intro →General Catalyst
38 Life Sciences deals in the last 24 months · 24 at a nearby stage · 34 in US West Coast
Request intro →Andreessen Horowitz
22 Life Sciences deals in the last 24 months · 11 at a nearby stage · 20 in US West Coast
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 10 at a nearby stage · 20 in US West Coast
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 6 at a nearby stage · 15 in US West Coast
Request intro →Lightspeed
16 Life Sciences deals in the last 24 months · 10 at a nearby stage · 14 in US West Coast
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.